Model‐Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia
Open Access
- 31 October 2025
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (2) , 322-335
Abstract
Model‐informed drug development (MIDD) played a crucial role in the successful development and regulatory approval of daprodustat, a novel oral hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHI) inhibitor aimed at treating anemia in chronic kidney disease patients. MIDD was pivotal in optimizing dosing strategies and enabling effective dose individualization, ensuring the right dose for the right patient. This tutorial illustrates how integrated quantitative approaches, including longitudinal hemoglobin response modeling, population pharmacokinetics (PopPK), and clinical trial simulations, were applied to guide phase III dose selection, inform trial design, and support regulatory interactions. We highlight the evolution and application of these models, emphasizing key development decisions, challenges encountered, and insights gained.Keywords
This publication has 37 references indexed in Scilit:
- Integrated Longitudinal Population Dose‐Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney DiseaseClinical Pharmacology & Therapeutics, 2025
- Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting ProgramClinical Pharmacology & Therapeutics, 2024
- The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to PathwayClinical Pharmacology & Therapeutics, 2024
- Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development ParadigmClinical Pharmacology & Therapeutics, 2023
- Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability DeterminationClinical Pharmacology in Drug Development, 2021
- The Drug Titration Paradox: Correlation of More Drug With Less Effect in Clinical DataClinical Pharmacology & Therapeutics, 2021
- Proceedings of a Workshop: Precision Dosing: Defining the Need and Approaches to Deliver Individualized Drug Dosing in the Real‐World SettingClinical Pharmacology & Therapeutics, 2020
- Model‐Informed Drug Development: Current US Regulatory Practice and Future ConsiderationsClinical Pharmacology & Therapeutics, 2019
- Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and DocumentationCPT: Pharmacometrics & Systems Pharmacology, 2015
- Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863Clinical Pharmacology in Drug Development, 2013